FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
作者信息
Shahswar Rabia, Beutel Gernot, Klement Piroska, Rehberg Alina, Gabdoulline Razif, Koenecke Christian, Markel Dominik, Eggers Hendrik, Eder Matthias, Stadler Michael, Hambach Lothar, Ehrlich Steve, Göhring Gudrun, Schlegelberger Brigitte, Dammann Elke, Reuter Marlene, Wichmann Martin, Neziri Blerina, Ganser Arnold, Thol Felicitas, Heuser Michael
机构信息
Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Department of Human Genetics, Hannover Medical School, Hannover, Germany.
出版信息
Br J Haematol. 2020 Feb;188(3):e11-e15. doi: 10.1111/bjh.16268. Epub 2019 Nov 4.
Abstract
摘要
相似文献
1
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.复发/难治性急性白血病患者使用氟达拉滨-IDA挽救性化疗联合为期7天的维奈克拉治疗方案（FLAVIDA）
Br J Haematol. 2020 Feb;188(3):e11-e15. doi: 10.1111/bjh.16268. Epub 2019 Nov 4.
2
Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.维奈托克联合FLAG-IDA治疗难治性或复发性急性髓系白血病
Eur J Haematol. 2025 Jan;114(1):17-25. doi: 10.1111/ejh.14302. Epub 2024 Sep 9.
3
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.维奈托克联合 FLAG-IDA 诱导和巩固治疗新诊断和复发/难治性急性髓系白血病。
J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27.
4
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.维奈克拉联合HAG方案挽救了复发/难治性早期T细胞前体急性淋巴细胞白血病。
Ann Hematol. 2020 Feb;99(2):395-397. doi: 10.1007/s00277-019-03902-9. Epub 2019 Dec 26.
5
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.维奈克拉联合阿糖胞苷和/或伊达比星治疗复发/难治性儿童急性髓系白血病的 1 期、剂量递增研究。
Lancet Oncol. 2020 Apr;21(4):551-560. doi: 10.1016/S1470-2045(20)30060-7. Epub 2020 Mar 11.
6
FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias.FLAG 与 FLAG-IDA：复发/难治性急性白血病的结局。
Cancer Chemother Pharmacol. 2019 Jun;83(6):1191-1193. doi: 10.1007/s00280-019-03792-8. Epub 2019 Feb 13.
7
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.氟达拉滨、阿糖胞苷和伊达比星联合或不联合维奈托克治疗复发/难治性急性髓系白血病患者。
Haematologica. 2024 Jan 1;109(1):72-83. doi: 10.3324/haematol.2023.282912.
8
FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children.FLAG方案（氟达拉滨、大剂量阿糖胞苷和粒细胞集落刺激因子）用于儿童难治性和高危复发性急性白血病。
Med Pediatr Oncol. 2000 Feb;34(2):163. doi: 10.1002/(sici)1096-911x(200002)34:2<163::aid-mpo21>3.0.co;2-6.
9
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.FLAG-Ida联合或不联合吉妥珠单抗-奥佐米星挽救治疗难治性/复发性急性髓系白血病成年患者生存的预后模型
Br J Haematol. 2016 Sep;174(5):700-10. doi: 10.1111/bjh.14107. Epub 2016 Apr 26.
10
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.氟达拉滨、阿糖胞苷联合伊达比星治疗难治性/复发性成人急性淋巴细胞白血病
Ann Hematol. 2005 Nov;84(12):792-5. doi: 10.1007/s00277-005-1090-9. Epub 2005 Nov 12.
引用本文的文献
1
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.一种用于接受维奈托克联合去甲基化药物治疗的难治性/复发性急性髓系白血病患者的新型预后风险模型。
Leukemia. 2025 Mar;39(3):614-622. doi: 10.1038/s41375-024-02501-6. Epub 2025 Jan 8.
2
Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.维奈托克联合FLAG-IDA治疗难治性或复发性急性髓系白血病
Eur J Haematol. 2025 Jan;114(1):17-25. doi: 10.1111/ejh.14302. Epub 2024 Sep 9.
3
A case of co-occurring acute myeloid leukemia and relapsed diffuse large B-cell lymphoma in a young adult with Shwachman-Diamond syndrome.一名患有施瓦茨曼-戴蒙德综合征的年轻成人同时发生急性髓系白血病和复发性弥漫性大B细胞淋巴瘤的病例。
Pediatr Blood Cancer. 2024 Aug;71(8):e31137. doi: 10.1002/pbc.31137. Epub 2024 Jun 4.
4
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study.克拉屈滨、小剂量阿糖胞苷和维奈克拉治疗复发/难治性急性髓系白血病的疗效与安全性：一项试点研究的结果
Blood Cancer J. 2024 Jan 18;14(1):12. doi: 10.1038/s41408-024-00982-3.
5
Venetoclax: A Game Changer in the Treatment of Younger AML Patients?维奈托克：年轻急性髓系白血病患者治疗的变革者？
Cancers (Basel). 2023 Dec 22;16(1):73. doi: 10.3390/cancers16010073.
6
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.氟达拉滨、阿糖胞苷和伊达比星联合或不联合维奈托克治疗复发/难治性急性髓系白血病患者。
Haematologica. 2024 Jan 1;109(1):72-83. doi: 10.3324/haematol.2023.282912.
7
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions.维奈托克在复发/难治性急性髓系白血病中的作用：过去、现在及未来方向
Bioengineering (Basel). 2023 May 13;10(5):591. doi: 10.3390/bioengineering10050591.
8
Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia.在一名原发性诱导失败的急性髓系白血病患者中，氟达拉滨（FLAM）与维奈克拉联合阿扎胞苷序贯组合用于过渡至脐血移植。
Case Rep Oncol. 2022 Nov 8;15(3):974-979. doi: 10.1159/000526697. eCollection 2022 Sep-Dec.
9
The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia.BH3模拟药物维奈克拉在急性髓系白血病治疗中日益重要的作用
Mediterr J Hematol Infect Dis. 2022 Nov 1;14(1):e2022080. doi: 10.4084/MJHID.2022.080. eCollection 2022.
10
BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia.BCL-2抑制剂与PI3Kδ抑制剂协同作用，克服急性髓系白血病中的FLT3抑制剂耐药性。
Am J Cancer Res. 2022 Aug 15;12(8):3829-3842. eCollection 2022.
本文引用的文献
1
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.维奈克拉联合阿扎胞苷可破坏急性髓系白血病患者的能量代谢并靶向白血病干细胞。
Nat Med. 2018 Dec;24(12):1859-1866. doi: 10.1038/s41591-018-0233-1. Epub 2018 Nov 12.
2
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.在 AML 患者进行异基因造血细胞移植前，通过 NGS 进行可测量残留病监测。
Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6.
3
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.维奈克拉与去甲基化药物联合治疗复发/难治性急性髓系白血病的疗效
Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.
4
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.抑制 Mcl-1 增强了 Bcl-2 选择性抑制剂 ABT-199 在急性髓系白血病细胞中诱导的细胞死亡。
Signal Transduct Target Ther. 2017 Apr 7;2:17012. doi: 10.1038/sigtrans.2017.12. eCollection 2017.
5
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Venetoclax 联合治疗复发/难治性急性髓系白血病及相关髓系恶性肿瘤的临床经验。
Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23.
6
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.挽救治疗方案对诱导失败的急性髓系白血病患者缓解率和总生存率的影响。
Leukemia. 2017 Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19.
7
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
8
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.维奈托克单药治疗急性髓性白血病患者的II期研究中的疗效及反应的生物学关联
Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.
9
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
10
Mitochondria-Judges and Executioners of Cell Death Sentences.线粒体——细胞死亡判决的评判者与执行者
Mol Cell. 2016 Mar 3;61(5):695-704. doi: 10.1016/j.molcel.2016.02.019.
Zotero 插件